Caseware UK (AP4) 2022.0.179 2022.0.179 2023-03-312023-03-31true2022-04-01falseOther professional, scientific and technical activities not elsewhere classified33trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 07580832 2022-04-01 2023-03-31 07580832 2021-04-01 2022-03-31 07580832 2023-03-31 07580832 2022-03-31 07580832 c:Director3 2022-04-01 2023-03-31 07580832 d:PlantMachinery 2022-04-01 2023-03-31 07580832 d:OtherPropertyPlantEquipment 2022-04-01 2023-03-31 07580832 d:OtherPropertyPlantEquipment 2023-03-31 07580832 d:OtherPropertyPlantEquipment 2022-03-31 07580832 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2022-04-01 2023-03-31 07580832 d:CurrentFinancialInstruments 2023-03-31 07580832 d:CurrentFinancialInstruments 2022-03-31 07580832 d:Non-currentFinancialInstruments 2023-03-31 07580832 d:Non-currentFinancialInstruments 2022-03-31 07580832 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 07580832 d:CurrentFinancialInstruments d:WithinOneYear 2022-03-31 07580832 d:ShareCapital 2023-03-31 07580832 d:ShareCapital 2022-03-31 07580832 d:SharePremium 2023-03-31 07580832 d:SharePremium 2022-03-31 07580832 d:RetainedEarningsAccumulatedLosses 2023-03-31 07580832 d:RetainedEarningsAccumulatedLosses 2022-03-31 07580832 c:OrdinaryShareClass1 2022-04-01 2023-03-31 07580832 c:OrdinaryShareClass1 2023-03-31 07580832 c:OrdinaryShareClass1 2022-03-31 07580832 c:OrdinaryShareClass2 2022-04-01 2023-03-31 07580832 c:OrdinaryShareClass2 2023-03-31 07580832 c:OrdinaryShareClass2 2022-03-31 07580832 c:FRS102 2022-04-01 2023-03-31 07580832 c:AuditExempt-NoAccountantsReport 2022-04-01 2023-03-31 07580832 c:FullAccounts 2022-04-01 2023-03-31 07580832 c:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 07580832









SPOTON CLINICAL DIAGNOSTICS LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2023

 
SPOTON CLINICAL DIAGNOSTICS LIMITED
REGISTERED NUMBER: 07580832

STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2023

2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 4 
17,643
39,799

Current assets
  

Stocks
 5 
66,356
56,988

Debtors: amounts falling due after more than one year
 6 
7,600
-

Debtors: amounts falling due within one year
 6 
84,961
30,838

Cash at bank and in hand
 7 
1,235,144
1,021,806

  
1,394,061
1,109,632

Creditors: amounts falling due within one year
 8 
(133,913)
(80,572)

Net current assets
  
 
 
1,260,148
 
 
1,029,060

  

Net assets
  
1,277,791
1,068,859


Capital and reserves
  

Called up share capital 
 9 
235
235

Share premium account
  
139,896
139,896

Profit and loss account
  
1,137,660
928,728

  
1,277,791
1,068,859


The directors consider that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

Page 1

 
SPOTON CLINICAL DIAGNOSTICS LIMITED
REGISTERED NUMBER: 07580832
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2023

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:



C Turner
Director

Date: 23 November 2023

The notes on pages 3 to 8 form part of these financial statements.
Page 2

 
SPOTON CLINICAL DIAGNOSTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

1.


General information

Spoton Clinical Diagnostics Limited is a private limited company incorporated in England and Wales. The address of the registered office is Suite 10,First Floor, Qmb Innovation Centre, 42 New Road, London, 
E1 2AX. The principal activity of the company is clinical diagnostic testing, reagent provision, and analytical support.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Foreign currency translation

Functional and presentation currency

The company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Page 3

 
SPOTON CLINICAL DIAGNOSTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

2.Accounting policies (continued)

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the company has transferred the significant risks and rewards of ownership to the buyer;
the company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.4

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates income.

 
2.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 
SPOTON CLINICAL DIAGNOSTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

2.Accounting policies (continued)


2.5
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on the following basis:.


Plant & machinery
-
20%
straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.6

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in the Statement of comprehensive income.

 
2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.10

Financial instruments

Financial instruments are recognised in the company's Statement of Financial Position when the company becomes party to the contractual provisions of the instrument.

Page 5

 
SPOTON CLINICAL DIAGNOSTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

2.Accounting policies (continued)

 
2.11

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 3 (2022 - 3).


4.


Tangible fixed assets





Plant and machinery

£



Cost or valuation


At 1 April 2022
272,909


Additions
17,643



At 31 March 2023

290,552



Depreciation


At 1 April 2022
233,110


Charge for the year
39,799



At 31 March 2023

272,909



Net book value



At 31 March 2023
17,643



At 31 March 2022
39,799

Page 6

 
SPOTON CLINICAL DIAGNOSTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

5.


Stocks

2023
2022
£
£

Finished goods and goods for resale
66,356
56,988

66,356
56,988



6.


Debtors

2023
2022
£
£

Due after more than one year

Other debtors
7,600
-

7,600
-


2023
2022
£
£

Due within one year

Trade debtors
77,978
20,683

Prepayments and accrued income
6,983
10,155

84,961
30,838



7.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
1,235,144
1,021,806

1,235,144
1,021,806


Page 7

 
SPOTON CLINICAL DIAGNOSTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

8.


Creditors: Amounts falling due within one year

2023
2022
£
£

Corporation tax
72,570
45,648

Other taxation and social security
9,322
7,271

Accruals and deferred income
52,021
27,653

133,913
80,572



9.


Share capital

2023
2022
£
£
Allotted, called up and fully paid



141,036 (2022 - 141,036) Ordinary subscriber shares of £0.0010 each
141
141
94,024 (2022 - 94,024) Ordinary shares of £0.0010 each
94
94

235

235



10.


Controlling party

There is no ultimate controlling party

 
Page 8